Insulin Degludec Injection (Tresiba®)

Phase 3

Insulin Degludec Injection (Tresiba®) is one of 3 therapeutic programs targeting Type 2 Diabetes (T2DM). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 2 Diabetes (T2DM)Recruiting

Type 2 Diabetes (T2DM)Phase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Type 2 Diabetes (T2DM)

#DrugCompanyPhaseTrials

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 2

Metformin XR

AstraZeneca

Phase 2

1 3

Insulin Degludec Injection (Tresiba®)

GGan & Lee Pharmaceuticals.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Type 2 Diabetes (T2DM)

NCT07527078

Clinical

Trials by Indication[1]

Type 2 Diabetes (T2DM)1 trial

A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs

Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07527078·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Insulin Degludec Injection (Tresiba®). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Insulin Degludec Injection (Tresiba®). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gan & Lee Pharmaceuticals. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: GGan & Lee Pharmaceuticals.

Insulin Degludec Injection (Tresiba®)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Type 2 Diabetes (T2DM)1 trial

References

Drug Info

Quick Facts

Related News